ImmunoGen, Inc. has received $-0.38 as the consensus Earnings Estimate for the Quarter ending on Dec 2016 ,According to the estimate provided by 5 Financial Advisor in the Stock Trading Firms. Among 5 Analysts, Bottom line EPS Estimate for the current quarter is $-0.45 while the top line estimate is $-0.34 , a key information to consider for Day Trading and investing in stocks. The EPS growth rate is projected at 1.05%.
ImmunoGen, Inc. results fell short with a surprise EPS of -21.05% or $-0.08. The Actual EPS was $-0.46 compared to the Estimated EPS of $-0.38 during its most recent quarterly earnings.
In the last quarter, ImmunoGen, Inc. reported Annual Earnings of $-0.46. Based on the filings, last years Annual Earnings was, $-1.65. In the last Quarter, IMGN reported a surprise Earnings per Share of -21.05% . The consensus estimate for current quarter is $-0.38 and for the current fiscal year, the estimate is $-1.65. For the Next fiscal year, the estimate is $-1.56 based on the consensus.
ImmunoGen, Inc. (NASDAQ:IMGN) : On Tuesday heightened volatility was witnessed in ImmunoGen, Inc. (NASDAQ:IMGN) which led to swings in the share price. The stock opened for trading at $2.31 and hit $2.3899 on the upside , eventually ending the session at $2.34, with a gain of 0.43% or 0.01 points. The heightened volatility saw the trading volume jump to 1,354,888 shares. The 52-week high of the share price is $9.78 and the company has a market cap of $204 million. The 52-week low of the share price is at $1.51 .
ImmunoGen, Inc. develops pharmaceuticals, primarily for the treatment of cancer. The companys product candidates are called tumor-activated prodrugs and are based on its proprietary immunoconjugate technology platform. Unlike conventional chemotherapeutic agents, tumor-activated prodrugs are intended to deliver potent chemotherapy specifically to a tumor. Each tumor-activated drug immunoconjugate comprises a small-molecule drug which has been chemically linked to a monoclonal antibody.